|
HMG-CoA Reductase Inhibitors
|
risk of myopathy and rhabdomyolysis
|
|
Anticoagulants
|
warfarin dosage should be reduced
|
|
CYP2C8 Substrates
|
drugs metabolized CYP2C8 (e.g., dabrafenib, loperamide, montelukast, paclitaxel, pioglitazone, rosiglitazone) may be required to reduce
|
|
OATP1B1 substrates
|
substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan) may be required to reduce
|
|
Bile Acid-Binding Resins
|
resin-granule drugs such as colestipol (5 g) are recommended at 2 or more hours apart
|
|
Colchicine
|
myopathy, including rhabdomyolysis in chronic administration of colchicine
|
